Hal Barron, GSK R&D chief (GSK via investor day livestream)
July 29, 2021 10:10 AM EDTUpdated 11:07 AM
R&D

What made Glax­o­SmithK­line’s Hal Bar­ron spend $2.2B to get back in­to neu­ro? Alec­tor flash­es the da­ta

Jason Mast

Editor

What made GSK’s Hal Bar­ron spend $700 mil­lion cash to get in on a pair of an­ti­bod­ies for neu­rode­gen­er­a­tion?

Alec­tor flashed part of the an­swer …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times